{"entity":{"id":"da-trial-prasinezumab","kind":"trial","name":"Prasinezumab (PASADENA / related)","aka":[],"tldr":"Prasinezumab was studied in early Parkinson’s disease as an anti-alpha-synuclein antibody. It is not a dementia approval.","summary":"Kept as a cited synuclein programme neighbour for Lewy-body biology on this atlas. Parkinson’s results do not equal a dementia label.","status":"completed","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov NCT03100149","url":"https://clinicaltrials.gov/study/NCT03100149"}],"tags":["dementia-atlas"],"related":[],"cancers":["parkinsons-disease-dementia"],"sections":[],"technologies":[],"targets":[],"drugs":["da-prasinezumab"],"companies":["da-roche"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03100149","phase":"2","setting":"Early Parkinson’s disease","sponsor":"Roche","outcomes":[]},"route":"/trials/da-trial-prasinezumab/","neighbours":{"cancer":[{"id":"parkinsons-disease-dementia","kind":"cancer","name":"Parkinson’s disease dementia","route":"/diagnoses/parkinsons-disease-dementia/"}],"drug":[{"id":"da-prasinezumab","kind":"drug","name":"Prasinezumab","route":"/drugs/da-prasinezumab/"}],"company":[{"id":"da-roche","kind":"company","name":"Roche","route":"/companies/da-roche/"}]}}